THCP
Tetrahydrocannabiphorol · THCP · Discovered 2019
Learn about THCP (Tetrahydrocannabiphorol), the ultra-potent cannabinoid discovered in 2019 with 33 times the CB1 binding affinity of THC. Explore its extreme potency, safety concerns, and research implications.
Psychoactive
Yes
Discovered
2019
Effects
6 documented
Benefits
2 studied
Overview
Tetrahydrocannabiphorol (THCP) is a naturally occurring cannabinoid discovered in 2019 by Italian researchers led by Dr. Cinzia Citti. The discovery, published in the journal Scientific Reports, sent shockwaves through the cannabis science community because THCP demonstrated a binding affinity for CB1 receptors approximately 33 times greater than Delta-9 THC. This extraordinary potency is attributed to THCP's elongated seven-carbon alkyl side chain, compared to THC's five-carbon chain. The longer chain allows THCP to fit more deeply and securely into the CB1 receptor binding pocket.
The discovery of THCP has significant implications for understanding cannabis pharmacology. It may help explain why some cannabis strains produce disproportionately strong effects relative to their measured THC content — even trace amounts of THCP could substantially amplify the overall psychoactive experience. The researchers who discovered THCP estimated that an Italian medical cannabis variety (FM2) contained THCP at concentrations of approximately 0.0023%, a tiny amount that could nonetheless contribute meaningfully to overall potency.
The commercial market has begun producing THCP-infused products, which has raised serious safety concerns. Given THCP's extreme potency, even small dosing errors could lead to overwhelming psychoactive experiences. The compound has virtually no human safety data, and its long-term effects are completely unknown. Regulatory agencies have not established safe dosing guidelines, and the potential for adverse events with this ultra-potent cannabinoid is considerably higher than with conventional THC products.
Mechanism of Action
THCP binds to CB1 receptors with approximately 33 times the affinity of Delta-9 THC, as demonstrated in radioligand binding assays. This dramatically enhanced binding is attributed to its seven-carbon (heptyl) alkyl side chain, which extends deeper into the hydrophobic binding pocket of the CB1 receptor than THC's five-carbon chain. The relationship between side chain length and CB1 binding affinity follows a well-established structure-activity relationship in cannabinoid pharmacology, where chains longer than five carbons generally increase potency up to a maximum around eight carbons. THCP also binds to CB2 receptors with enhanced affinity compared to THC (approximately 5-10 times greater). In functional cannabinoid tetrad assays in mice (measuring analgesia, hypothermia, catalepsy, and hypolocomotion), THCP was active at significantly lower doses than THC, confirming its enhanced in vivo potency.
Therapeutic Effects
Potential Benefits
Treatment-Resistant Pain
Theoretical. THCP's dramatically enhanced CB1 binding affinity suggests it could be effective for pain conditions that do not respond adequately to conventional THC. However, no human studies have been conducted, and the enhanced potency also raises the risk of adverse effects. Any medical application would require extremely precise micro-dosing.
Understanding Cannabis Potency Variation
Scientific evidence. The discovery of THCP provides a potential explanation for why some cannabis strains feel more potent than their THC percentage would predict. Even trace amounts of THCP in certain cultivars could significantly amplify subjective effects, contributing to the pharmacological complexity of whole-plant cannabis.
Side Effects & Risks
- ⚠Extremely potent psychoactive effects — high risk of overconsumption
- ⚠Severe anxiety, paranoia, and panic at excessive doses
- ⚠Pronounced sedation and motor impairment
- ⚠No established human safety profile
- ⚠Unknown long-term health effects
- ⚠Will trigger positive drug tests for THC
- ⚠Potential for significant cognitive impairment
- ⚠High risk of adverse events due to potency and lack of dosing guidelines
Concentration & Sources
Typical Concentration
Approximately 0.001-0.003% in natural cannabis; available in concentrated forms in commercial products, typically blended with other cannabinoids at 1-5% of total formulation
Found In
Trace amounts in certain cannabis cultivars, first identified in the Italian medical variety FM2. Commercially produced through synthesis or semi-synthesis. Available in THCP-infused vape cartridges, edibles, and tinctures, usually blended with other cannabinoids.
Legal Status
Unscheduled at the federal level in the US but likely falls under the Federal Analogue Act as a THC analog. Banned in several states. Not specifically addressed in most international drug laws. Regulatory status is highly uncertain.
Research Summary
THCP research consists primarily of the landmark 2019 discovery paper by Citti et al. in Scientific Reports, which characterized the compound's structure, confirmed its natural occurrence in cannabis, and demonstrated its extraordinary CB1 binding affinity (33x THC) through radioligand binding assays and in vivo tetrad testing in mice. Beyond this foundational study, published research on THCP is extremely limited. The discovery has had its greatest impact on cannabis science by highlighting that the cannabis plant contains many more pharmacologically active compounds than previously appreciated, and that minor constituents can have outsized effects. Safety and toxicology studies are urgently needed given the commercial availability of THCP products, but none have been published as of 2025.
Related Cannabinoids
THCP FAQ
How potent is THCP compared to THC?
THCP has approximately 33 times the binding affinity for CB1 receptors compared to Delta-9 THC in laboratory binding assays. In functional tests in mice, THCP produced the same effects as THC (pain relief, reduced movement, lowered body temperature, catalepsy) at significantly lower doses. However, binding affinity does not translate linearly to subjective potency in humans — THCP is likely several times more potent than THC in practice but not necessarily 33 times stronger in perceived effect.
Is THCP safe?
The safety of THCP is unknown. There are no published human clinical trials, no established safe dosing guidelines, and no long-term safety data. Given its extreme potency (33x THC binding affinity), the risk of accidental overconsumption and adverse events is significantly higher than with conventional THC. Commercial THCP products are unregulated and should be approached with extreme caution. Starting doses should be very small (1mg or less), and products should only be purchased from companies providing comprehensive third-party testing.
Is THCP natural or synthetic?
THCP is a naturally occurring cannabinoid first identified in a cannabis variety in 2019 by Italian researchers. It exists in the plant in extremely low concentrations (around 0.001-0.003%). However, the commercial THCP found in consumer products is typically produced through semi-synthesis or chemical modification to achieve the quantities needed for commercial formulations, as natural extraction would be prohibitively expensive.
Is THCP legal?
THCP's legal status is highly uncertain. It is not specifically scheduled in the US Controlled Substances Act, but as a structural analog of THC with enhanced psychoactive potency, it likely falls under the Federal Analogue Act in jurisdictions where that applies. Several states have specifically banned THCP or included it in broader bans on hemp-derived psychoactive cannabinoids. Given its extreme potency and lack of safety data, additional regulatory action is likely.
Continue Exploring
Disclaimer: Cannabinoid information is provided for educational purposes only. Medical benefits are based on published research and are not intended as medical advice. Individual responses to cannabinoids vary. Always consult a healthcare professional before using cannabis for medical purposes. Legal status information is current as of publication but may change — verify your local laws.